Acute granulomatous tubulointerstitial nephritis caused by intravesical BCG
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
A 72-year-old lady of Chinese ethnicity was referred because of an elevated plasma creatinine. She had a history of grade 3 transitional cell carcinoma (TCC) of the left ureter diagnosed 2 years previously. This had been treated by nephroureterectomy; the operative specimens showed widespread carcinoma in situ (CIS) involving the ureter, but the kidney and operative margins were free from malignancy. Recurrent grade 3, non-invading (T1) TCC and CIS of the bladder were detected on screening cystoscopy 3 months prior to referral. The tumour was treated by cauterization and a course of intravesical baccile Calmette–Guerin (BCG) was started for the CIS. Five weekly instillations of 81 mg of Connaught strain BCG were administered. No significant episodes of cystitis were noted during therapy. Serum creatinine had been 120 µmol/l since the time of nephrectomy until last measured 1 month prior to referral. Past medical history included hypercholesterolaemia and hypertension. Medications were ezetimibe and metoprolol. The patient presented 7 days after the fifth BCG instillation with a low-grade fever and mild left-sided flank pain and tenderness. Urinalysis showed sterile pyuria without haematuria or proteinuria. Full blood count was normal; erythrocyte sedimentation rate and C-reactive protein were both moderately elevated at 85 mm/h (normal: 0–35 mm/h) and 95 mg/l (normal: 0–5.0 mg/l), respectively. Serum creatinine was 190 µmol/l and urea was 13.9 mmol/l; electrolytes and calcium were normal. The creatinine continued to rise to 277 µmol/l over the following week. Liver function tests and chest radiograph were normal. The left kidney and renal artery blood flow appeared normal on ultrasonographic examination. Plasma complement and anti-nuclear antibody titres were normal. Anti-neutrophil cytoplasmic antibody was slightly elevated. There was no serological evidence of hepatitis B or C infection. Urine cultures for mycobacterium were negative. A percutaneous needle biopsy of the single kidney was performed using computerized tomographic localization and showed diffuse tubulointerstitial nephritis ( Figure 1 ). A patchy inflammatory infiltrate included lymphocytes, plasma cells, histiocytes and a moderate number of eosinophils. Tubular degeneration was evident on light microscopy and intramural lymphocytes were seen on electron microscopy. At least two non-necrotizing granulomas were present ( Figure 2 ). Acid-fast bacilli or fungal hyphae were not seen and immunohistochemistry for mycobacterium was negative. Glomeruli appeared normal, arterioles showed medial nodular changes consistent with a hypertensive effect and there was mild interstitial fibrosis. There was a trace of mesangial staining for immunoglobulin M and C3 on immunofluorescence. Renal biopsy showing tubulointerstitial nephritis. There is an inflammatory infiltrate of lymphocytes, plasma cells, histiocytes and a moderate number of eosinophils. Degenerating tubules are seen. Haemotoxylin and eosin staining. Magnification: ×400. Renal biopsy showing granuloma. At least two non-necrotizing granulomas were present within the interstitium. Mycobacteria or fungal hyphae were not seen. Haemotoxylin and eosin staining. Magnification: ×400. Therapy was initiated with oral prednisone, 50 mg daily. Serial measures of serum creatinine showed a rapid improvement in renal function and then gradual return to baseline ( Figure 3 ). The patient has remained well throughout a 7 month period of close clinical observation; she has been afebrile and has not shown any features to suggest mycobacterial infection. A recent cystoscopy with biopsies showed no evidence of TCC recurrence. Recovery of renal function. Graph of serum creatinine from presentation to time of writing. Rapid improvement of renal function after initiation of prednisolone is seen, followed by a gradual return of creatinine to pre-BCG levels. TCC of the lower urinary tract occurs in most industrialized Western nations with an incidence of about 18 per 100 000 population in males and seven per 100 000 in females [ 1 ]. Intravesical BCG has been an established therapy for preventing recurrence and treating CIS since being approved for this use by the FDA in 1990 (reviewed in [ 1 ]). The anti-tumour action of BCG has not been fully elucidated, but appears to be due to a local immune response following phagocytosis of the BCG antigen. There is upregulation of chemokines, cytokines and adhesion molecules facilitating T cell-, macrophage- and neutrophil-mediated elimination of cancer cells [ 2 ]. This localized immune response leads to the most frequently reported side effects of urinary frequency, dysuria, low-grade fever and malaise [ 3 ]. BCG incorporates a live-attenuated vaccine and, as such, may cause infection. Infection occurs extremely rarely after use of BCG as immunization against tuberculosis, but is seen more commonly after intravesical use [ 4 ]. Haematogenous spread of mycobacterium may occur aft
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, several exceptional cases of interstitial nephritis and glomerulonephritis, with or without associated granulomatosis, have been described in the literature [5-8].”
In the citing paper
“Although corticosteroid therapy effectively mitigates the active inflammatory component, renal function recovery remains predominantly partial [5-8, 13-16].”
In the citing paper
“From a histological and pathophysiological standpoint, the literature confirms the predominance of acute or chronic interstitial nephritis, frequently associated with non-caseating epithelioid granulomas [5-8].”
In the citing paper
“Although corticosteroid therapy effectively mitigates the active inflammatory component, renal function recovery remains predominantly partial [5-8, 13-16].”
In the citing paper
“This case is remarkable for its exceptionally long and unusual latency period, which generally manifests within days to months in other patients.”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lamm, D. L., Van Der Meijden, A. P. M., Morales, A., Brosman, S. A., Catalona, W. J., Herr, H. W., Soloway, M. S., Steg, A., & Debruyne, F. M. J. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37316-0 · Cited by 786
BCG immunotherapy of bladder cancer: 20 years on
Alexandroff, A. B., Jackson, A. M., O'Donnell, M. A., & James, K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07422-4 · Cited by 471
Efficacy and Safety of Bacille Calmette-Guérin Immunotherapy in Superficial Bladder Cancer
Lamm, D. L. (2000) · Clinical Infectious Diseases · doi:10.1086/314064 · Cited by 264
Mechanisms of Action of Intravesical Bacille Calmette-Guérin: Local Immune Mechanisms
Prescott, S. M., Jackson, A. M., Hawkyard, S., ALEXANDROFF, A. B., & James, K. E. (2000) · Clinical Infectious Diseases · doi:10.1086/314066 · Cited by 104
Complications of bacille Calmette-Guérin (BCG) vaccination and immunotherapy and their management.
Jm, G. (1998) · PubMed · Cited by 88
Molina, J.-M., Rabian, C., D’agay, M.-F., & Modai, J. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37354-8 · Cited by 70
Drug-induced acute interstitial nephritis with granulomas
Magil, A. B. (1983) · Human Pathology · doi:10.1016/s0046-8177(83)80044-6 · Cited by 62
Outryve, S. V., Francque, S., Gentens, P., Pauw, F. F. D., den Bogaert, E. V., Marck, E. A. V., Pelckmans, P. A., & Michielsen, P. P. (2004) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200410000-00012 · Cited by 34
Renal complications of intravesical bacillus Calmette-Guérin therapy
Modesto, A., Marty, L., Suc, J.-M., Kleinknecht, D., de Frémont, J.-F., Marsepoil, T., & Veyssier, P. (2008) · American Journal of Nephrology · doi:10.1159/000168368 · Cited by 30
BCG Pyelonephritis following Intravesical BCG
Kondratowicz, G. M., & WALLACE, D. M. A. (1989) · British Journal of Urology · doi:10.1111/j.1464-410x.1989.tb05329.x · Cited by 6
Cited by
Medication-Induced Interstitial Nephritis in the 21st Century
Nast, C. C. (2017) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2016.11.016 · Cited by 88
Complications of Intravesical Bacillus Calmette-Guérin
Macleod, L. C., Ngo, T. C., & Gonzalgo, M. L. (2014) · Canadian Urological Association Journal · doi:10.5489/cuaj.1411 · Cited by 51
Tubulointerstitial nephritis and cancer chemotherapy: update on a neglected clinical entity
Airy, M., Raghavan, R., Truong, L. D., & Eknoyan, G. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft241 · Cited by 35
Etiological diagnosis of granulomatous tubulointerstitial nephritis in the tropics
Agrawal, V., Kaul, A., Prasad, N., Sharma, K., & Agarwal, V. (2015) · Clinical Kidney Journal · doi:10.1093/ckj/sfv071 · Cited by 34
Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed
Assayag, M., Rouvier, P., Gauthier, M., Costel, G., Cluzel, P., Mercadal, L., Deray, G., & Bagnis, C. I. (2017) · BMC Cancer · doi:10.1186/s12885-017-3705-7 · Cited by 27
Metadata
- Authors
- Kennedy, S. E., Shrikanth, S., & Charlesworth, J. A.
- Affiliations
- Prince of Wales Hospital (AU)
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-02-01
- Volume
- 21
- Issue
- 5
- Pages
- 1427-1429
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2093404446
- Cited by
- 17
- References
- 10
- Citations by year
- 2026: 1 · 2023: 2 · 2022: 1 · 2020: 2 · 2017: 3 · 2016: 1 · 2015: 2 · 2014: 1 · 2013: 2
- FWCI
- 0.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nephrology Dialysis Transplantation (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Urology › Urinary Tract Infections Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- BCG immunotherapy, bladder cancer, carcinoma in situ, urothelial carcinoma, acute kidney injury, nephroureterectomy, antineutrophil cytoplasmic antibodies
- MeSH terms
- Acute Disease, Administration, Intravesical, Aged, BCG Vaccine, Biopsy, Needle, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Cystoscopy, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Granuloma, Humans, Immunohistochemistry, Kidney Function Tests, Nephritis, Interstitial, Prednisone, Treatment Outcome, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.